Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: Feb 18, 2025 · CIK: 1581178
Sentiment: neutral
Topics: filing, press-release
TL;DR
Eupraxia Pharma (EPRX) filed a 6-K on Feb 18, 2025, with a press release attached. Check for updates.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on February 18, 2025, reporting for the month of February 2025. The filing includes Exhibit 99.1, a press release dated February 18, 2025. The company is incorporated in Canada and its principal executive office is located in Victoria, British Columbia.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' reporting status and includes a press release, which may contain material information for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release, with no immediate financial or operational disclosures that suggest high risk.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- February 18, 2025 (date) — Filing date and press release date
- Alex Roth (person) — Signatory for the filing
- 001-41923 (other) — SEC File Number
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report for the month of February 2025 and to include Exhibit 99.1, which is a press release dated February 18, 2025.
What is the filing date of this report?
This report was filed as of February 18, 2025.
Where is Eupraxia Pharmaceuticals Inc. located?
Eupraxia Pharmaceuticals Inc.'s principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada.
What exhibit is included as part of this report?
Exhibit 99.1, a Press Release dated February 18, 2025, is included as part of this report.
Who signed this report on behalf of Eupraxia Pharmaceuticals Inc.?
Alex Roth signed this report on behalf of Eupraxia Pharmaceuticals Inc.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on February 18, 2025 by Alex Roth regarding EUPRAXIA PHARMACEUTICALS INC. (EPRX).